The efficacy of permethrin-treated bed nets on child mortality and morbidity in western Kenya II. Study design and methods

被引:49
|
作者
Phillips-Howard, PA
ter Kuile, FO
Nahlen, BL
Alaii, JA
Gimnig, JE
Kolczak, MS
Terlouw, DJ
Kariuki, SK
Shi, YP
Kachur, SP
Hightower, AW
Vulule, JM
Hawley, WA
机构
[1] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30341 USA
[2] Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya
[3] Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
来源
关键词
D O I
10.4269/ajtmh.2003.68.10
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This paper describes the study design and methods used in a large community-based, group-randomized, controlled trial of permethrin-treated bed nets (ITNs) in an area with intense, perennial malaria transmission in western Kenya conducted between 1996 and 1999. A multi-disciplinary framework was used to explore the efficacy of ITNs in the reduction of all-cause mortality in children less than five years old, the clinical, entomologic, immunologic, and economic impact of ITNs, the social and behavioral determinants of ITN use, and the use of a geographic information system to allow for spatial analyses of these outcomes. Methodologic difficulties encountered in such large-scale field trials are discussed.
引用
收藏
页码:10 / 15
页数:6
相关论文
共 23 条
  • [21] A MALARIA CONTROL TRIAL USING INSECTICIDE-TREATED BED NETS AND TARGETED CHEMOPROPHYLAXIS IN A RURAL AREA OF THE GAMBIA, WEST-AFRICA .2. MORTALITY AND MORBIDITY FROM MALARIA IN THE STUDY AREA
    ALONSO, PL
    LINDSAY, SW
    SCHELLENBERG, JRMA
    GOMEZ, P
    HILL, AG
    DAVID, PH
    FEGAN, G
    CHAM, K
    GREENWOOD, BM
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1993, 87 : 13 - 17
  • [22] An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
    Shoji, Tadahiro
    Komiyama, Shinichi
    Kigawa, Junzo
    Tanabe, Hiroshi
    Kato, Kazuyoshi
    Itamochi, Hiroaki
    Fujiwara, Hiroyuki
    Kamiura, Shoji
    Hamano, Tetsutaro
    Sugiyama, Toru
    BMC CANCER, 2018, 18
  • [23] An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
    Tadahiro Shoji
    Shinichi Komiyama
    Junzo Kigawa
    Hiroshi Tanabe
    Kazuyoshi Kato
    Hiroaki Itamochi
    Hiroyuki Fujiwara
    Shoji Kamiura
    Tetsutaro Hamano
    Toru Sugiyama
    BMC Cancer, 18